Screener
Cullinan Therapeutics, Inc. CGEM Free cash flow
Discontinued — last reported Q4 '25
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Cullinan Therapeutics, Inc.’s reported figures.
The source filing: Cullinan Therapeutics, Inc.’s 10-K, filed March 10, 2026. Open the filing →
- Filed
- Mar 10, 2026, 7:26 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001193125-26-099362
FAQ
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- Cullinan Therapeutics, Inc. (CGEM) reported free cash flow of -$38.12M in Q4 2025.
- How has Cullinan Therapeutics, Inc.'s free cash flow changed year-over-year?
- Cullinan Therapeutics, Inc.'s free cash flow decreased by 4.1% year-over-year, from -$36.63M to -$38.12M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s free cash flow?
- Over 2 years (2022 to 2024), Cullinan Therapeutics, Inc.'s free cash flow has grown at a 6.6% compound annual growth rate (CAGR), from -$127.8M to -$145.3M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Cullinan Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude